Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

Schaule, Jana; Kroeze, S.G.C.; Blanck, Oliver; Stera, Susanne; Kahl, Klaus Henning; Roeder, Falk; Combs, Stephanie E.; Kaul, David; Claes, An; Schymalla, Markus M.; Adebahr, S.; Eckert, Franziska; Lohaus, Fabian; Abbasi-Senger, N.; Henke, Guido; Szuecs, Marcella; Geier, Michael; Sundahl, Nora; Buergy, Daniel; Dummer, Reinhard; Gückenberger, Matthias

doi:10.1186/s13014-020-01708-y

Cited by 3 publications

(2 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…found a correlation between actual and predicted overall survival according to ds-GPA score in a cohort of over 350 patients with 0-10 brain metastases ( 33 ), except for a worse than predicted OS in the subgroup of patients with adenocarcinoma of the lung and a ds-GPA score of 2.5-4.0. Recently, the ds-GPA could not be validated in a cohort of patients with melanoma, putatively due to the effects of immunotherapy and targeted therapies ( 34 ). This group suggested a novel approach to predictive scoring using a combination of tumour volume, timing of onset and any systemic therapies, which reflects the continual personalization of therapy for patients with brain metastases ( 34 ).…”

Section: Discussionmentioning

confidence: 99%

“…Recently, the ds-GPA could not be validated in a cohort of patients with melanoma, putatively due to the effects of immunotherapy and targeted therapies ( 34 ). This group suggested a novel approach to predictive scoring using a combination of tumour volume, timing of onset and any systemic therapies, which reflects the continual personalization of therapy for patients with brain metastases ( 34 ).…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Radiosurgery for Five to Fifteen Brain Metastases: A Single Centre Experience and a Review of the Literature

et al. 2022

View full text Add to dashboard Cite

PurposeStereotactic radiosurgery (SRS) is now mainstream for patients with 1-4 brain metastases however the management of patients with 5 or more brain metastases remains controversial. Our aim was to evaluate the clinical outcomes of patients with 5 or more brain metastases and to compare with published series as a benchmarking exercise.MethodsPatients with 5 or more brain metastases treated with a single isocentre dynamic conformal arc technique on a radiosurgery linac were identified from the institutional database. Endpoints were local control, distant brain failure, leptomeningeal disease and overall survival. Dosimetric data were extracted from the radiosurgery plans. Series reporting outcomes following SRS for multiple brain metastases were identified by a literature search.Results36 patients, of whom 35 could be evaluated, received SRS for 5 or more brain metastases between February 2015 and October 2021. 25 patients had 5-9 brain metastases (group 1) and 10 patients had 10-15 brain metastases (group 2). The mean number of brain metastases in group 1 was 6.3 (5-9) and 12.3 (10-15) in group 2. The median cumulative irradiated volume was 4.6 cm3 (1.25-11.01) in group 1 and 7.2 cm3 (2.6-11.1) in group 2. Median follow-up was 12 months. At last follow-up, local control rates per BM were 100% and 99.8% as compared with a median of 87% at 1 year in published series. Distant brain failure was 36% and 50% at a median interval of 5.2 months and 7.4 months after SRS in groups 1 and 2 respectively and brain metastasis velocity at 1 year was similar in both groups (9.7 and 11). 8/25 patients received further SRS and 7/35 patients received whole brain radiotherapy. Median overall survival was 10 months in group 1 and 15.7 months in group 2, which compares well with the 7.5 months derived from the literature. There was one neurological death in group 2, leptomeningeal disease was rare (2/35) and there were no cases of radionecrosis.ConclusionWith careful patient selection, overall survival following SRS for multiple brain metastases is determined by the course of the extracranial disease. SRS is an efficacious and safe modality that can achieve intracranial disease control and should be offered to patients with 5 or more brain metastases and a constellation of good prognostic factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Radiosurgery for Five to Fifteen Brain Metastases: A Single Centre Experience and a Review of the Literature

et al. 2022

View full text Add to dashboard Cite

show abstract

Prosopis juliflora (Sw.) DC phytochemicals induce apoptosis and inhibit cell proliferation signaling pathways, EMT, migration, invasion, angiogenesis and stem cell markers in melanoma cell lines

Choudhari

Nimma

Nimal

et al. 2023

Journal of Ethnopharmacology

View full text Add to dashboard Cite

Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases

Tan

Scherrer

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

BackgroundMore than 60% of all stage IV melanoma patients develop brain metastases, while melanoma brain metastases (MBM) is historically difficult to treat with poor prognosis.ObjectivesTo summarize clinical outcomes and prognostic factors in MBM patients.MethodsA systematic review with meta-analysis was conducted, and a literature search for relevant studies was performed on November 1, 2020. Weighted average of median overall survival (OS) was calculated by treatments. The random-effects model in conducting meta-analyses was applied.ResultsA total of 41 observational studies and 12 clinical trials with our clinical outcomes of interest, and 31 observational studies addressing prognostic factors were selected. The most common treatments for MBM were immunotherapy (IO), MAP kinase inhibitor (MAPKi), stereotactic radiosurgery (SRS), SRS+MAPKi, and SRS+IO, with median OS from treatment start of 7.2, 8.6, 7.3, 7.3, and 14.1 months, respectively. Improved OS was observed for IO and SRS with the addition of IO and/or MAPKi, compared to no IO and SRS alone, respectively. Several prognostic factors were found to be significantly associated with OS in MBM.ConclusionThis study summarizes pertinent information regarding clinical outcomes and the association between patient characteristics and MBM prognosis.

show abstract

Correction to: Predicting survival in melanoma patients treated with concurrent targeted- or immunotherapy and stereotactic radiotherapy

Abstract: An amendment to this paper has been published and can be accessed via the original article.

Cited by 3 publications

References 1 publication

Radiosurgery for Five to Fifteen Brain Metastases: A Single Centre Experience and a Review of the Literature

Radiosurgery for Five to Fifteen Brain Metastases: A Single Centre Experience and a Review of the Literature

Prosopis juliflora (Sw.) DC phytochemicals induce apoptosis and inhibit cell proliferation signaling pathways, EMT, migration, invasion, angiogenesis and stem cell markers in melanoma cell lines

Systematic literature review and meta-analysis of clinical outcomes and prognostic factors for melanoma brain metastases

Contact Info

Product

Resources

About